newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288

  • Ascentage Pharma received U.S. FDA investigational new drug (IND) clearance for APG-3288, a next-generation BTK-targeted protein degrader.
  • The company will conduct a global, multicenter, open-label Phase I study to evaluate the safety, tolerability, pharmacokinetic profile, & preliminary efficacy of APG-3288.
  • The study targets patients with relapsed/refractory B-cell malignancies, including B-cell lymphoma, chronic lymphocytic leukemia, & Waldenström's macroglobulinemia.
  • APG-3288 utilizes Ascentage Pharma's proprietary PROTAC technology to induce proteasome-mediated degradation of BTK rather than conventional inhibition.
  • This degradation mechanism is designed to overcome resistance caused by BTK mutations & signaling pathway remodeling associated with existing BTK inhibitors.
  • Preclinical data indicates APG-3288 demonstrates potent degradation of both wild-type BTK & multiple resistance-associated BTK mutants with high selectivity & favorable PK properties.
  • The drug candidate is intended to block the BCR-BTK signaling axis at its source to provide a differentiated therapeutic strategy for hematologic malignancies.
  • Ascentage Pharma plans to accelerate global clinical development of APG-3288 & explore its combinatory potential with existing proprietary small-molecule agents.
  • APG-3288 remains under investigation & has not received final approval from the U.S. FDA.